Ocugen Inc

Change company Symbol lookup

Select an option...

OCGN Ocugen Inc

NEGG Newegg Commerce Inc

PHX PHX Minerals Inc

IRT Independence Realty Trust Inc

RLAY Relay Therapeutics Inc

CVU CPI Aerostructures Inc

MA Mastercard Inc

WDBG Neuro-Hitech Inc

GLRY Inspire Faithward Mid Cap Momentum ETF

WCC Wesco International Inc

Go

Ocugen, Inc. is a biopharmaceutical company focused on developing gene therapies to cure blindness diseases and developing vaccine for COVID-19. The Company's technology pipeline includes: COVID-19 Vaccine (0.5), Modifier Gene Therapy Platform and Novel Biologic Therapies for Retinal Diseases. COVID-19 Vaccine candidate is focused on developing, manufacturing and commercializing COVAXIN for the prevention of COVID-19 in humans in the Ocugen Covaxin Territory. COVAXIN is a whole-virion inactivated COVID-19 vaccine candidate and is formulated with the inactivated SARS-CoV-2 virus. The Modifier Gene Therapy platform is designed for retinal diseases, including retinitis pigmentosa (RP), leber congenital amaurosis (LCA) and dry age-related macular degeneration (AMD). It is developing OCU200, a biologic product candidate to treat diabetic macular edema (DME), diabetic retinopathy (DR) and wet AMD. OCU400, its first product candidate being developed with its modifier gene therapy platform.